Day of Life Sciences
The symposium «Competencies in Drug Discovery» aims to discuss projects from different therapeutic indications in an interdisciplinary way and to promote the interaction of biological, chemical and medical competencies.
2022: 13th Day of Life Sciences «Competencies in Drug Discovery»
Sponsors
Exhibitors
Culture Collection of Switzerland, IGZ Instruments AG, Chemie Brunschwig AG, Welmedis GmbH, CEM GmbH, Eurofins Discovery, Promega AG, Büchi Labortechnik AG, Merck/Sigma Aldrich, Sysmex Suisse AG, Thermo Fisher Scientific (Schweiz) AG
- Thursday, June 9th, 2022 (registration deadline: June 7th, 2022)
- Venue: ZHAW Life Sciences and Facility Management, Grüentalstrasse 14, 8820 Wädenswil(PDF 3,0 MB)
- Programme flyer(PDF 434,2 KB)
- Costs: CHF 150
- Contact: info.icbt@zhaw.ch
Content, goals
Pharmaceutical research is of great importance to society as it represents a major industry and improves people's lives. In this context, drug discovery and development are crucial steps in improving treatment options for patients. These are challenging and highly interdisciplinary projects with a high degree of complexity. Meeting these challenges requires diverse collaboration between different scientific disciplines as well as between academia and industry.
A Center of Excellence for Drug Discovery is therefore being established at the Institute of Chemistry and Biotechnology at ZHAW to foster, support and successfully implement these collaborations. The symposium «Competencies in Drug Discovery» aims to discuss projects from different therapeutic indications in an interdisciplinary way and to promote the interaction of biological, chemical and medical competencies.
Programme
| 08.30 | Registration |
|---|---|
| 09.00 |
Welcome to the ZHAW, news and outlook Prof. Dr. Christian Hinderling, Zurich University of Applied Sciences (CH) |
| 09.15 |
Drug Discovery Competence Center Prof. Dr. Rainer Riedl, Zurich University of Applied Sciences (CH) |
| 09.30 |
A topical drug for a tropical bug: How a Swiss academic/private network is developing BAC-ZHAWOC-6027 to treat cutaneous leishmaniasis Dr. Michael Adams, Bacoba AG (CH) |
| 10.00 |
Approaches towards innovative antibiotics from myxobacterial natural products Prof. Dr. Rolf Müller, Helmholtz Centre for Infection Research (DE) |
| 10.30 | Coffee break with poster session |
| 11.00 |
Antivirals discovery against paramyxoviruses PD Dr. Philippe Plattet, University of Bern (CH) |
| 11.30 |
The treasure hunt of novel antibiotics produced by actinomycetes: lessons from the R&D of glycopeptides Prof. Dr. Flavia Marinelli, Università degli Studi dell’Insubria (IT) |
| 12.00 | Networking lunch and exhibition |
| 13.30 |
Metabolomics assisted natural product discovery from marine fungi Prof. Dr. Deniz Tasdemir, GEOMAR Helmholtz Centre for Ocean Research Kiel (DE) |
| 14.00 |
Development of small molecules to block CD93-signaling in leukemia patients Prof. Dr. Carsten Riether, Bern University Hospital (CH) |
| 14.30 |
Bioactive natural products from bacteria: how much do we know Prof. Dr. Jörn Piel, ETH Zurich (CH) |
| 15.00 | Coffee break with poster session |
| 15.30 |
Enhancing NO/sGC/cGMP pathway with new soluble guanylyl cyclase (sGC) agonists Prof. Dr. Manolis Fousteris, University of Patras (GR) |
| 16.00 |
Performance Boosted Antibiotics and Drug-Loaded Microbots Against Bacterial Infections Prof. Dr. Karl Gademann , University of Zurich (CH) |
| 16.30 |
USP18 as a checkpoint for IFN signaling and ISG15 deconjugation: From ko mice via structural analysis to therapeutic options PD Dr. Klaus-Peter Knobeloch, University Clinic Freiburg (DE) |
| 17.00 | Aperitif and networking |
Review
2021 - 3rd CCBIO Symposium on «Industrial Biocatalysis»
In a transdisciplinary environment, the 3rd CCBIO Symposium on Industrial Biocatalysis will provide a platform for scientific knowledge transfer and dialog for participants from industry and academia and bring together renowned researchers to discuss recent advances and future directions of the field.
2019 - Hydroxyanthracene Derivatives Symposium
The Hydroxyanthracene Derivatives Symposium featured cutting-edge contributions about analysis, quality, safety and efficacy of this interesting phytochemical substance class. It also provided a platform for dialogue and scientific knowledge transfer for participants from industry, regulatory bodies, academia or education.
Flyer «Analysis, Safety, Quality and Efficacy in Herbal Medicinal Products - April 11th»
2018 - Second Symposium of Industrial Biocatalysis
The Second Symposium of Industrial Biocatalysis hosted speakers from Switzerland and abroad who talked about current challenges in the field.
2017 - ICBT: Factories of the future
What will the future bring? Our students will design them. That's why, together with our partners from industry and research, we are already developing the latest technologies that map the production processes of tomorrow. Amongst others, we present techniques such as flow chemistry, microreactor technology and 3D printing for personalized implants and entire fabrics.
2016 - Industrial Biocatalysis
Biocatalysis enables the sustainable production of chiral and highly functionalized compounds for the chemical and pharmaceutical industry. The Competence Centre of Biocatalysis at the ZHAW promotes biocatalysis as a complementary method to classic organic synthesis. It aims to help bridge the gap between academic laboratories and the production plant.
2015 - Frontiers in Personalized Medicine
A Precision Medicine initiative in the USA, announced by President Obama in January 2015, is designed to promote wider use of patient-specific medical care. The aim is to deliver new and more effective treatments for diseases. But what is going on in this ambitious, challenging field in Switzerland and in Europe?
Download speeches
- Current and future trends in personalized medicine, Dr. Bruce Jordan, Roche Diagnostics(PDF 3,5 MB)
- International Ltd Challenges of personalized health for clinical medicine, Prof. Dr. Peter Meier-Abt, Swiss Academy of Medical Scienes, Basel(PDF 2,5 MB)
- Implementing research in personalized medicine, Prof. Dr. Niko Beerenwinkel, ETH Zürich, Competence Center Personalized Medicine(PDF 1,8 MB)
- Osteosarcoma: Current perspectives and future development, Prof. Dr. Bruno Fuchs, Sarcoma Center UZH, University Hospital Balgrist(PDF 7,3 MB)
- Gene therapy in ophthalmology – the TargetAMD project, Dr. Martina Kropp, University Hospital Geneva(PDF 2,1 MB)
- TEDD information, Prof. Dr. Ursula Graf-Hausner, Zurich University of Applied Sciences(PDF 1,7 MB)
- Sciences Exhibition slam(PDF 3,2 MB)
2014 - Neue Materialien aus Holz – nahe oder ferne Zukunft?
In der Verwendung von Holz als Baustein für chemische Produkte und zur Herstellung neuartiger Verbundstoffe liegt ein grosses Potenzial für die Ablösung der global noch stark erdölbasierten Materialwirtschaft. Der 6. Chemietag der ZHAW widmet sich den vielfältigen wissenschaftlichen und unternehmerischen Herausforderungen, die sich in der Forschung und Entwicklung innovativer holzbasierter Materialien aktuell stellen.
Download Referate
- Aktivitäten am Institut für Chemie und Biologische Chemie, Prof. Dr. Christian Hinderling, Institutsleiter ICBT, ZHAW, Wädenswil(PDF 2,2 MB)
- Innovations-Suchfelder für holzbasierte Materialien, Dr. Willi Schwotzer, Psetta GmbH, Neuenkirch(PDF 2,2 MB)
- Polymere Nanoverbundswerkstoffe mit Zellulose Nanofasern, Prof. Dr. Christoph Weder, Adolphe Merkle Institut, Marly(PDF 6,1 MB)
- Holz als Chemierohstoff: Extraktion von Tanninen aus Rinden heimischer Nadelhölzer, Dr. Fédéric Pichelin, Berner Fachhochschule, Biel(PDF 1,4 MB)
- Wasserfeste, dimensionsstabile LVL aus Buchenholz, Prof. Dr. Holger Militz, Georg-Augst-Universität, Göttingen(PDF 2,2 MB)
- Bio-inspirierte Materialien aus Holz, Prof. Dr. Ingo Bugert, ETH Zürich(PDF 1,8 MB)
2013 - Didaktik in der Chemie
Im Fokus dieser Veranstaltung stehen aktuelle didaktische Herausforderungen im Unterricht an Berufs- und Fachhochschulen. Diese tragen zum Erfolg des dualen Bildungssystems in der Schweiz bei. Zudem hat die Bologna-Reform zu einer Internationalisierung beigetragen, die ein länderübergreifendes Qualitätsmanagement nötig erscheinen lässt (Eurobachelor).
2012 - Solar Energy - Chemical Solutions
Sunlight is the most abundant and reliable source of energy available to humanity. In order to provide a truly widespread primary energy source, solar energy must be harvested, converted, and stored in a cost-effective manner. These three key steps require scientific and technological breakthroughs. Chemistry contributes to this development by creating new materials for capturing sunlight, converting light to electricity, enabling light-driven reactions, or increasing the long-term stability of solar cells.
Download speeches (slides)
- Photovoltaics in Switzerland - the cycle of research, technology, industry and markets, Dr. Stefan Nowak, Programme Manager, Swiss Photovoltaic Research Programme, Swiss Federal Office of Energy(PDF 3,4 MB)
- Modeling and simulation of photoelectrochemical cells, Dr. Matthias Schmid, ZHAW(PDF 2,5 MB)
- New trends in organic materials based solar cells, Prof. Dr. Frank Nüesch, EMPA(PDF 3,9 MB)
- Running chemical reactions at ultra-high temperatures for solar energy storage - potential and challenges, Dr. Ivo Alxneit, Solar Technology Laboratory, PSI(PDF 10,2 MB)
2011 - Medicinal Chemistry
The pharmaceutical industry is of global economic importance. As a central component, drug development is a complex process that requires interdisciplinary research and development. Only the effective collaboration of different scientific disciplines enables the development of new medicines for the benefit of patients.
Download speeches (slides)
- Drug discovery in the academic setting, Rainer Riedl, ZHAW(PDF 6,0 MB)
- VIBRANT a European Project for Betacell Imaging and Quantification Theo Schotten, CAN GmbH(PDF 5,4 MB)
- Blocking AMRE - Chemistry and Biochemistry at a Nasty Enzyme, Andreas Natsch, Fridtof Schröder, Givaudan Schweiz AG(PDF 1,3 MB)
- VirtualToxLab TM - In silico prediction of the toxic potential of drugs and chemicals, Angelo Vedani, Departement of Pharmaceutical Sciences, University of Basel(PDF 3,0 MB)
- Discovery of the Novel, Orally Active S1P Receptor Agonist ACT-128800 (Ponesimod), Martin Bolli, Actelion Pharmaceuticals Ltd(PDF 3,7 MB)